US FDA orders ESA labelling changes to narrow use
This article was originally published in Scrip
Executive Summary
The US FDAhas ordered labelling changes for erythropoiesis-stimulating agents (ESAs) to advise against use in patients receiving chemotherapy in the adjuvant setting and place a haemoglobin level ceiling for initiation of treatment. However, the FDA opted not to restrict use of the anaemia treatments in patients according to tumour types, despite a recommendation to the contrary by its oncologic drugs advisory panel.
You may also be interested in...
FibroGen May Have A New Opening For Roxadustat In The US
The company announced positive Phase II data for roxadustat in chemotherapy-induced anemia.
Accelerated Approval Is US FDA Panel’s Preferred Path For Biogen/Ionis’s Tofersen In ALS
Advisory committee unanimously concludes that the reduction in plasma neurofilament light chain concentration is reasonably likely to predict clinical benefit in SOD1-ALS, but majority of panelists say convincing evidence of efficacy to support regular approval has not been demonstrated.
Electronic Records: US FDA Updates Guidelines On Use In Clinical Investigations
Revised draft guidance includes recommendations on preparing for FDA inspections, considerations for real-world data and digital health technologies, and the need for service level agreements between sponsors and IT providers.